<DOC>
	<DOC>NCT01969201</DOC>
	<brief_summary>The purpose of the non-inferiority study is to evaluate the clinical efficacy and the safety of two different subcutaneous FSH preparations (Fostimon versus Gonal-F) for controlled ovarian hyperstimulation in a GnRH-antagonist cycle.</brief_summary>
	<brief_title>FSH in GnRH-AntagoniST Controlled Ovarian Hyperstimulation Cycles (FAST)</brief_title>
	<detailed_description />
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Ovarian Hyperstimulation Syndrome</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Follicle Stimulating Hormone</mesh_term>
	<criteria>Age: 1838 years old; BMI: 1828 kg/m2; Less than 3 previously completed IVF cycles; Basal FSH &lt;10 IU/L and E2 &lt;80 pg/ml; TSH &lt; 2.5 mIU/L &gt;10 and &lt;30 antral follicles 210 mm in size for both ovaries combined AMH: &gt;1 ng/ml (7.15 pmol/l) and &lt;5.6 ng/ml (40.0 pmol/l) Presence and adequate visualization of both ovaries; Within 12 months of the beginning of the study, uterine cavity consistent with expected normal function as assessed through transvaginal ultrasound, hysterosalpingogram, sonohysterogram or hysteroscopic examination; Primary ovarian failure or women known as poor responders; PCO and PCOS; Severe OHSS in a previous COH cycle; Uterine malformation that may impair the possibility to get pregnant; Ovarian cysts &gt;10 mm; Hydrosalpinx that have not been surgically removed or ligated; Endometriosis stage 3 or 4; Oocyte donation; Severe male factor; Pathologies associated with any contraindication of being pregnant; History of recurrent miscarriage (more than 3 previous miscarriages); Hypersensitivity to the study medication; Abnormal bleeding of undetermined origin; Uncontrolled thyroid or adrenal dysfunction; Neoplasias; Severe impairment of renal and/or hepatic function.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>38 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>In vitro fertilization (IVF)</keyword>
	<keyword>Assisted reproduction technologies (ART)</keyword>
	<keyword>GnRH-antagonist</keyword>
	<keyword>Follicle stimulating hormone (FSH)</keyword>
</DOC>